[Effects of a new vasoactive substance on renal hemodynamics].
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D001966:Bromine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005921:Glomerulonephritis / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000098:blood supply* / Q000503:physiopathology; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D012039:Regional Blood Flow / Q000187:drug effects
D004873:Ergolines; D009539:Nicotinic Acids; D000804:Angiotensin II; D001966:Bromine; D009638:Norepinephrine
Effetti di una nuova sostanza vasoattiva sull'emodinamica renale.